JP2021507707A5 - - Google Patents

Info

Publication number
JP2021507707A5
JP2021507707A5 JP2020534373A JP2020534373A JP2021507707A5 JP 2021507707 A5 JP2021507707 A5 JP 2021507707A5 JP 2020534373 A JP2020534373 A JP 2020534373A JP 2020534373 A JP2020534373 A JP 2020534373A JP 2021507707 A5 JP2021507707 A5 JP 2021507707A5
Authority
JP
Japan
Application number
JP2020534373A
Other languages
Japanese (ja)
Other versions
JP2021507707A (ja
JPWO2019123018A5 (https=
JP7841847B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/001620 external-priority patent/WO2019123018A2/en
Publication of JP2021507707A publication Critical patent/JP2021507707A/ja
Priority to JP2023192505A priority Critical patent/JP2024009058A/ja
Publication of JPWO2019123018A5 publication Critical patent/JPWO2019123018A5/ja
Publication of JP2021507707A5 publication Critical patent/JP2021507707A5/ja
Application granted granted Critical
Publication of JP7841847B2 publication Critical patent/JP7841847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020534373A 2017-12-21 2018-12-20 ラッサワクチン Active JP7841847B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192505A JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609155P 2017-12-21 2017-12-21
US62/609,155 2017-12-21
PCT/IB2018/001620 WO2019123018A2 (en) 2017-12-21 2018-12-20 Lassa vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192505A Division JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Publications (4)

Publication Number Publication Date
JP2021507707A JP2021507707A (ja) 2021-02-25
JPWO2019123018A5 JPWO2019123018A5 (https=) 2026-01-26
JP2021507707A5 true JP2021507707A5 (https=) 2026-01-26
JP7841847B2 JP7841847B2 (ja) 2026-04-07

Family

ID=65763665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020534373A Active JP7841847B2 (ja) 2017-12-21 2018-12-20 ラッサワクチン
JP2023192505A Pending JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192505A Pending JP2024009058A (ja) 2017-12-21 2023-11-10 ラッサワクチン

Country Status (11)

Country Link
US (1) US11976305B2 (https=)
EP (1) EP3727411A2 (https=)
JP (2) JP7841847B2 (https=)
KR (1) KR102822230B1 (https=)
CN (1) CN111886342B (https=)
AU (1) AU2018392826B2 (https=)
CA (1) CA3085224A1 (https=)
MX (1) MX2020006476A (https=)
SG (1) SG11202004899SA (https=)
WO (1) WO2019123018A2 (https=)
ZA (1) ZA202003070B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111206022A (zh) * 2020-02-20 2020-05-29 中国人民解放军军事科学院军事医学研究院 一种表达拉沙热病毒空衣壳的重组病毒及其制备方法
KR102404143B1 (ko) * 2020-04-21 2022-05-31 대한민국(질병관리청장) 라싸 바이러스 핵단백질에 특이적인 항체, 이를 생산하는 하이브리도마 세포주 및 이를 이용한 라싸 바이러스 검출 키트
TWI815572B (zh) * 2021-09-27 2023-09-11 美商圖策智能科技有限公司 特定病毒的突變耐受表位的推估方法及系統
WO2026013289A1 (en) * 2024-07-12 2026-01-15 Institut Pasteur Measles-mumps-rubella (mmr) vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
WO2005012538A2 (en) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Accelerated vaccination
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
CA2774475A1 (en) 2009-09-16 2011-03-24 The Administrators Of The Tulane Educational Fund Lassa virus-like particles and methods of production thereof
EP3662935A1 (en) 2011-07-11 2020-06-10 Inovio Pharmaceuticals, Inc. Cross-protective arenavirus vaccines and their method of use
US11701418B2 (en) * 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses

Similar Documents

Publication Publication Date Title
JP2021507707A5 (https=)
BR122022016585A2 (https=)
BR212020012832U2 (https=)
BR202018071071U8 (https=)
BR112020025288A2 (https=)
BR202018008879U2 (https=)
BR202018007669U2 (https=)
BR202018006247U2 (https=)
BR202018004136U2 (https=)
BR202018002487U2 (https=)
BR202018002069U2 (https=)
CN304444593S (https=)
CN304453292S (https=)
CN304452644S (https=)
CN304451948S (https=)
CN304451472S (https=)
CN302894730S8 (https=)
CN302752841S8 (https=)
CN304449935S (https=)
CN304448519S (https=)
CN304448497S (https=)
CN304447878S (https=)
CN304446253S (https=)
CN304445491S (https=)
CN304453015S (https=)